Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
Orphan Drug
Advertisement
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
FastWave Medical Gains FDA IDE Approval for Artero IVL
Minneapolis, Minnesota, August,11, 2026 FastWave Medical has received U.S. Food and Drug Administration (FDA) approval of its Investigational Device...
EIT Pharma Gains FDA Acceptance for Lonafarnib NDA
Kirkland, Washington, August,11, 2026 EIT Pharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted...
Oculis Acquires Privosegtor to Expand Neuro-Ophthalmology
Zug, Switzerland & Barcelona, Spain, August 10, 2026 Oculis Holding AG and Accure Therapeutics S.L. have entered into an...
Advertisements
Jazz to Acquire Actio Biosciences for Rare Epilepsy Drug
Dublin, Ireland & San Diego, California, USA, August 10, 2026 Jazz Pharmaceuticals plc and Actio Biosciences, Inc. have announced...
Innate Pharma to Advance Lacutamab Toward Phase 3 with Sobi
MARSEILLE, France, August 10, 2026 Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of...
Scholar Rock Advances Apitegromab FDA Review with Second Fill-Finish Facility
CAMBRIDGE, Mass., August 7, 2026 Scholar Rock announced that the U.S. Food and Drug Administration (FDA) review of its...
Annexon Reports Rapid GBS Responses with Tanruprubart in FORWARD Study
BRISBANE, Calif., August 6, 2026 Annexon, Inc. announced encouraging early clinical results from the ongoing FORWARD open-label study, with...
Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
Advertisement
